Phosplatin Therapeutics, based in New York, is dedicated to addressing unmet needs in oncology immunotherapy through the development of innovative small molecule anti-cancer agents.
Their lead agent, PT-112, is a cutting-edge immunogenic cell death inducer, setting the standard as a best-in-class treatment option for cancer patients.
Generated from their website's infomation